Startup profile for Third Arc Bio: what they do, why they are interesting, stage (See coverage), industries, and links to our funding articles. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker Logo

Venture Capital Tracker

Startup profile · funding coverage

Third Arc Bio

Third Arc Bio develops multifunctional antibodies for oncology and immunology using immune-synapse biology.

Stage

See coverage

Status

private

Coverage

full

Why Third Arc Bio is interesting

Bispecific engagers need safer targeting; a16z led extension atop prior $165M Series A as ARC101 advances in solid tumors.

Key facts

  • Series A extension (Feb 2026): $52M led by a16z; Omega Funds and syndicate participated — Third Arc Bio press
  • Multifunctional antibodies for oncology and immunology; lead asset ARC101 in Phase 1
  • Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

Investors in our directory

Funds linked from Third Arc Bio's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Industries

Healthtech Biotech & Life Sciences

Industry hub pages are rolling out from our fund-derived baseline taxonomy.

Related funding articles

Venture Capital Tracker pieces that cover Third Arc Bio's financing or category context.

All startups Funding news

Last updated: 2026-07-24